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Differential inhibition of niesangial MAP kinase cascade by cyclic
nucleotides. The agents which increase intracellular cyclic AMP (cAMP)
or cyclic GMP (cGMP) have been found to counteract the effects of the
vasoconstrictive agents such as endothelin-1 (ET-1). To clarify the mech-
anism of this interaction, we evaluated the activities of mitogen-activated
protein kinase (MAPK) cascade, one of the important signal transduction
system of ET-1. Beraprost sodium, an analogue of PGI2, and ad-
renomedullin, a cAMP-raising agent, inhibited ET-1-induced activation of
MAPK. Dibutyryl cAMP (Bt2-cAMP) and 8-bromo-cGMP (8-Br-cGMP),
cell permeable analogues of cAMP and cGMP, were also able to inhibit
the activation of MAPK and MAPK kinase (MAPKK) by ET-1 without
interfering basal activities. In contrast, phorbol 12, 13-dibutylate (PDBu)-
induced activation of MAPK and MAPKK was inhibited by Bt2-cAMP but
not by 8-Br-cGMP. Interestingly, atrial natriuretic peptide (ANP) partially
inhibited PDBu-induced activation of MAPK and MAPKK. These results
indicate that cAMP and cGMP inhibit ET-1-induced activation of MAPK
in cultured mesangial cells at different steps; the former might inhibit at a
step downstream of PKC and the latter prior to PKC. The data also
suggest that ANP might have cGMP-independent effect on MAPK.
Vasoconstrictive peptides such as endothelin-1 (ET-1) and
angiotensin II bind to the specific receptors [1, 2] and induce the
contraction [3, 1 of glomerular mesangial cells, leading to a
reduction of capillary surface area necessary to glomerular filtra-
tion [5, 61. In addition to the vasoactive effect, ET-1 was found to
induce the proliferation of cultured mesangial cells [11. In con-
trast, the agents that could increase intracellular levels of cAMP
or cGMP were found not only to cause the relaxation of mesangial
cells, but to inhibit the contraction induced by vasoconstrictive
peptides 17—101. Moreover, cAMP- or cGMP-generating agents
have been reported to inhibit the proliferation of mesangial cells
[11—IS]. Therefore, various functions of mesangial cells are con-
sidered to be regulated by the interaction between vasoconstric-
tive and vasodilating agents. However, the mechanisms of the
interaction between these agents are still poorly understood.
Mitogen-activated protein kinase (MAPK) is an important
kinase in the intracellular signal transduction system of various
vasoconstrictors and growth factors [16—181. Since MAPK has
been reported to phosphorylate ribosomal S6 kinase II [191,
ternary complex factor Elk-i [20], cPLA2 [211, and actin binding
protein, h-caldesmon [221, the activation of MAPK may result in
various cellular responses including proliferation and contraction.
The importance of MAPK in cell contraction has been also
suggested by the observation that MAPK undergoes redistribu-
tion toward the vicinity of contractile filaments during vascular
smooth muscle cell activation [23]. Furthermore, MAPK cascade
has been shown to be involved in translational control of protein
synthesis [241. We and others have shown that ET-1 is able to
activate pp 44 and pp 42 MAPK in cultured mesangial cells and
have suggested that MAPK might be one of the main component
in the signal transduction of ET-1 [25, 26]. We have also reported,
in a preliminary form, that ANP is able to inhibit ET-1-induced
activation of MAPK in mesangial cells [261. Recently, the agents
which increase intracellular cAMP have been found to inhibit the
activation of MAPK induced by various growth factors in various
types of cells [27—31]. However, in certain types of cells, cAMP
was found to activate MAPK [32, 33] or to be without effect [34].
Thus, the present study was performed to examine whether cAMP
and cGMP could counteract the ability of ET-1 to activate MAPK
cascade in cultured glomerular mesangial cells.
Methods
Materials
ET-1 and ANP were purchased from Peptide Institute (Suita,
Japan), phorbol 12, 13-dibutylate (PDBu), bovine myelin basic
protein (MBP), dibutyryl cAMP (Bt2-cAMP) and 8-bromo-cGMP
(8-Br-cGMP) were bought from Sigma (St. Louis, MO, USA),
and FBS was obtained from Gibco (Grand island, NY, USA).
Beraprost sodium was a gift from Yamanouchi Pharmaceutical
Co. Ltd. (Tokyo, Japan) and adrenomedullin was purchased from
Peptide Institute (Suita, Japan), GST-ERK1 was purchased from
UBI (New York, NY, USA) and anti-MEK antisera were kindly
provided by Dr. Kun-Liang Guan from The University of Michi-
gan (Ann Arbor, MI, USA). y-[32P]ATP was bought from New
England Nuclear (Boston, MA, USA). All other reagents were of
chemical grade and purchased from standard suppliers.
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Mesangial cell culture and experimental protocol
Glomeruli were isolated from male Sprague-Dawley rats weigh-
ing 100 to 150 g by sieving with stainless steel and nylon meshes
under sterile conditions as previously described [35]. Isolated
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glomeruli were cultured in RPMI 1640 medium containing 20%
fetal bovine serum and antibiotics. Cultured cells were identified
as mesangial cells as previously described [36, 37]. The cells were
observed for the following characteristics: (1) survival in a me-
dium containing D-valine rather than L-valine, indicating the
existence of D-amino acid oxidase; (2) resistance to puromycin
aminonucleoside (10 jig/mI) and susceptibility to mitomycin C (10jig/mI); (3) possession of a large number of intracellular actin
bundles stained by peroxidase-conjugated heavy melo-myosin; (4)
receptors specific to angiotensin II and contraction in response to
angiotensin II. Confluent cells from the second to fifth passages
were used for the experiments.
Confluent mesangial cells in 60 mm dish were made quiescent
by reducing the concentrations of FBS to 0.4% for 48 hours,
rinsed twice with phosphate buffered saline (PBS) and preincu-
bated in an incubation medium [RPMI 1640 medium with 0.4%
bovine serum albumin (BSA; free fatty acid) and 20 mrvi HEPES,
pH 7.4] at 37°C for 30 minutes. Cells were first exposed to cAMP-
or cGMP-rising agents for 10 minutes and then to ET-1 or PDBu
for another 10 minutes at 37°C in an incubation medium. Cells
were then rinsed twice with ice-cold PBS, and lysed in 500 jil
ice-cold lysis buffer (25 mrvi Tris-HC1, pH 7.4, 25 mrvi NaCI, 80 mM
j3—glycerophosphate, I mi sodium orthovanadate, 1 mivi NaF, 10
m sodium pyrophosphate, 1 mi EGTA, 1 mrvs PMSF, 10 jig/mI
Icupeptin). Cells were scraped off the plate and sonicated twice at
4°C for 10 seconds. Cellular homogenates were centrifuged at
12,000 >< g at 4°C for 30 minutes and supernatants were used for
the kinase assay.
Measurement of MAPK activities
The activities of MAPK were measured by in vitro kinase assay
and in gel kinase assay using bovine MBP as a substrate as
previously described [25]. For the in vitro kinase assay, 10 p.l
samples were incubated at 25°C for 15 minutes in a final volume
Basal Adrenomedullin ET-1 El-i
(10—v M) (10 M) +adrenomedullin
Fig. 2. Effect of adrenomedullin on ET-1 -induced activation of MAPK in
cultured mesangial cells. Cells were treated with iO M adrenomedullin for
10 minutes, exposed to 10 M ET-1 for additional 10 minutes, and the
activities of MAPK were measured by in vitro kinase assay. Values are
mean SD (N = 3). p < 0.05 versus basal, #P < 0.05 versus ET-1.
of 40 jil containing 25 mrvi Tris-HC1, pH 7.4, 10 mM MgCl2, 1 mM
DTT, 1 mi EGTA, 1 jiM protein kinase inhibitor (PKI), 50 jiM
ATP, 2 jiCi y-[32P]ATP, and 20 jig MBP. Reactions were
terminated by adding 10 jil stopping solution (0.6% HC1, 1 mivi
ATP, 1% BSA). After centrifugation, an aliquot of the superna-
tant (15 jil) was spotted on a P81 filter (Whatman). The filter was
washed five times for at least five minutes each in 0.5% phospho-
ric acid, washed again in ethanol and dried. Radioactivity re-
mained on a filter was determined by Cerenkov.
For in gel kinase assay, lysate of cells (20 jig protein) was
applied to 10% SDS-polyaciylamide gel containing 0.5 mg/mI
MBP. After electrophoresis, SDS was removed by washing with
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Fig. 1. Effect of beraprost sodium on cellular cAMP (A) and ET-1 -induced activation of MAPK (B, C) in cultured glomerular mesangial cells. Cells were
treated with various concentrations of beraprost sodium for 10 minutes and cellular cAMP accumulation was measured (A). Cells were treated with iO
M or 10—6 M beraprost sodium for 10 minutes, exposed to 10 M ET-1 for additional 10 minutes, and the activities of MAPK were measured by in vitro
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Fig. 3. Inhibition of ET-1 -induced activation of
MAPK by Bt2-cAMP (A) or 8-Br-cGMP (B) in
cultured mesangial cells. Cells were treated with
i0 M Bt2-cAMP (A) or iO M 8-Br-cGMP
(B) for 10 minutes, exposed to 10—8 M ET-i for
additional 10 minutes, and the activities of
MAPK were measured by in vitro kinase assay.
Values are mean SD (N = 6). *P < 0.05,
°°P < 0.01 versus basal, #P < 0.05, ##P <
0.01 versus ET-1.
Fig. 4. Inhibition of ET-1-induced activation of
,, pp44 MAPK by Bt2-cAMP or 8-Br-cGMP in cultured
mesangial cells. Cells were treated with vehicle
"' pp42 (lane 1, 4), i0 M Bt2-cAMP (lane 2, 5) oriO M 8-Br-cGMP (lane 3, 6) for 10 minutes,
exposed to 10_s M ET-1 (lane 4 to 6) for
additional 10 minutes, and the activities of
MAPK were measured by in gel kinase assay. A
representative autoradiogram is shown.
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Fig. 5. Effects of Bt2-cAMP (A) and 8-Br-cGMP (B) on PDBu-induced activation of MAPK in cultured mesangial cells. Cells were treated with I O M
Bt2-cAMP (A) or i0 M 8-Br-cGMP (B) for 10 minutes, exposed to 1O M PDBu for additional 10 minutes, and the activities of MAPK were measured
by in vitro kinase assay. Values are mean so (N = 9). < 0.01 versus basal, #P < 0.01 versus ET-1.
buffer A (50 mtvi HEPES, pH 7.4 and 5 mi mercaptoethanol) y-[32P]ATP for the kinase reaction. The gel was then extensively
containing 20% 2-propanol. Proteins in a gel were denatured in washed with 5%trichloroacetic acid and 10 m sodium pyrophos-
buffer A with 6 M guanidine-HCI at room temperature for one phate and subjected to autoradiography.
hour and renatured in buffer A with 0.04% Tween-40 at 4°C for 16
hours. The gel was incubated at 30°C for one hour in a buffer (25 Measurement of MAPKK activities
mM HEPES, pH 7.4, 10 m MgCI2, 0.1 msi EGTA, 5 mrvi The activities of MAPKK were evaluated by measuring its
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protein) prepared as described above was incubated with 5 tl
anti-MEK antisera for two hours at 4°C. The immunoprecipitates
were recovered by incubating with protein G-sepharose (20 d,
Pharmacia) for one hour at 4°C, centrifuging and washing three
times with cell lysis buffer and once with a kinase buffer (18 mrvi
HEPES pH 7.5 10 m magnesium acetate, and 50 j.M ATP)
without ATP. The immunoprecipitates with anti-MEK antisera
were incubated with 2 g GST-MAPK in a kinase buffer at 30°C
for 15 minutes. The activities of GST-MAPK were measured by in
gel kinase assay using MBP as a substrate as described above.
Measurement of cellular cAMP
The quiescent mesangial cells on 35 mm 6 well plates were
rinsed three times with Hank's balanced salt solution (HBSS),
incubated with 1 mvi IBMX in HBSS at 37°C for 10 minutes and
then exposed to beraprost sodium for additional 10 minutes. The
reaction was stopped by aspirating the buffer and adding 1 ml
ice-cold 6% trichloroacetic acid. The cells were scraped off the
plate and sonicated. After centrifugation at 3,000 rpm for 20
minutes at 4°C, the supernatant was extracted five times with ethyl
ether saturated with water and lyophilized. The lyophilized sam-
pie was resuspended in water and cAMP was measured by
radioimmunoassay using cAMP assay kit (Yamasa, Chiba, Japan)
Statistical analysis
Results are expressed as means SD. Comparisons between
two groups were analyzed by Student's unpaired t-test. Compar-
isons among three or more groups were analyzed by one-way
analysis of variance (ANOVA) followed by Scheffe's test to
evaluate statistical significance between any two groups.
Results
EJfrcts of cAMP- or cGMP-rising agents on ET-1 -induced
activation of MAPK
ET-1 stimulated the activities of MAPK in a time- and concen-
tration-dependent manner with a maximal stimulation at 10
minutes and at 10 M ET-1 [38]. Thus, the cells were treated with
10—8 M ET-1 for 10 minutes in the following experiments.
Beraprost sodium, an analogue of prostaglandin 12, increased
cellular cAMP content in a dose-dependent manner (Fig. IA) and
inhibited ET-1-induced activation of MAPK in concentrations
**
ni
Basal
Fig. 6. Inhibitoiy effect of ANP on PDBu-induced activation of MAPK in
cultured mesangial cells. Cells were treated with iO M ANP for 10
minutes, exposed to iO M PDBu for additional 10 minutes, and the
activities of MAPK were measured by in vitro kinase assay. Values are
mean so (N = 3). p < 0.05, < 0.01 versus basal, #P < 0.05 versus
ET-1.
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Fig. 7. Effects of Bt2-cAMP, 8-Br-cGMP and ANP on PDBu-induced activation of MAPK in cultured mesangial cells. Cells were treated with vehicle (lane
1, 4, 7), iO M Bt2-cAMP (lane 2, 5), iO M 8-Br-cGMP (lane 3, 6), or iO M ANP (lane 8) for 10 minutes, exposed to i0 M PDBu (lane 4 to 6,
8) for additional 10 minutes, and the activities of MAPK were measured by in gel kinase assay. A representative autoradiogram is shown.
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*- GST-ERK 1
4— GST-ERK 1
on ET-1-induced activation of MAPK. As shown in Figure 3,
ET-1-induced activation of MAPK was significantly inhibited by
both Bt2-cAMP and 8-Br-cGMP. Again, basal activities of MAPK
was not influenced. To confirm the results obtained by the in vitro
kinase assay, the activities of MAPK were also measured by in gel
kinase assay. As shown in Figure 4, ET-1 activated both pp 44 and
pp 42 MAPK, and ET-1-induced activation of MAPK was inhib-
ited by both Bt2-cAMP and 8-Br-cGMP. In gel kinase assay, MBP
kinase with a molecular mass of approximately 60 kDa was also
detected. This MBP kinase might be ERK-3 [391,although further
identification is necessary. The activities of this MBP kinase seems
to be enhanced by ET-1 in the present experiment (Fig. 4, lane 1
and lane 4). However, we were unable to obtain a constant
activation [26, 38].
Effects of cAMP and cGMP on PDBu-induced activation of
MAPK
Because ET-1 -induced activation of MAPK was found to be
partly dependent on the activation of PKC, we next examined the
effect of cAMP and cGMP on PDBu-induced activation of
MAPK. PDBu-induced activation of MAPK was significantly
inhibited by Bt2-cAMP (Fig. 5A), while 8-Br-cGMP was without
effect (Fig. 5B). Interestingly, ANP was able to inhibit PDBu-
induced activation of MAPK (Fig. 6), although the degree of
inhibition by ANP was less than that by Bt2-cAMP. PDBu-
induced activation of MAPK was next examined by in gel kinase
assay. As shown in Figure 7, PDBu was able to activate both pp 44
and pp 42 MAPK and this activation was inhibited by Bt2-cAMP.
Again, 8-Br-cGMP did not inhibit PDBu-induced activation of
MAPK, while ANP was able to partially inhibit PDBu-induced
activation of MAPK.
Effects of cAMP and cGMP on MAPKK
1 2
4— GST-ERK 1
Fig. 8. Effects of Bt2-cAMP, 8-Br-cGMP and ANP on ET-i- or PDBu-
induced activation of MAPKK in cultured mesangial cells. A. Cells were
treated with vehicle (lane 1, 4), iO M Bt2-cAMP (lane 2, 5) or iO M
8-Br-cGMP (lane 3, 6) for 10 minutes and exposed to 10 M ET-1 (lane
4 to 6) for additional 10 minutes. B. Cells were treated with vehicle (lane
1, 4), iO M Bt2-cAMP (lane 2, 5) or i0 M 8-Br-cGMP (lane 3, 6) for
10 minutes and exposed to i0 M PDBu (lane 4 to 6) for additional 10
minutes. C. Cells were exposed to vehicle (lane 1, 3), or iO M ANP (lane
2, 4) and exposed to 10 M PDBu (lane 3, 4) for additional 10 minutes.
The activities of MAPKK were evaluated by measuring its ability to
activate GST-ERKI.
enough to stimulate cAMP production (Fig. 1 B, C), while basal
activities of MAPK were not influenced. Another cAMP-rising
agent, adrenomedullin, was also able to inhibit ET-1-induced
activation of MAPK (Fig. 2). We have already reported that ANP,
which increases cellular cGMP, could inhibit ET-1-induced acti-
vation of MAPK. Thus, we next examined the effects of Bt2-cAMP
and 8-Br-cGMP, cell permeable analogues of cAMP and cGMP,
We next examined the effects of cAMP and cGMP on ET-1- or
PDBu-induced activation of MAPKK. Both ET-1 and PDBu
activated MAPKK (Fig. 8 A and B, lane 4). Bt2-cAMP was able to
inhibit both ET-1- and PDBu-induced activation of MAPKK (Fig.
8 A and B, lane 5), while 8-Br-cGMP inhibited only ET-1-induced
activation of MAPKK. Interestingly, ANP was able to partially
inhibit PDBu-induced activation of MAPKK (Fig. 8C).
Discussion
The present results indicate that ET-1-induced activation of
MAPK cascade is inhibited by the agents that increase cellular
cAMP or cGMP in cultured glomerular mesangial cells. cAMP
was also able to inhibit PDBu-induced activation of MAPK, while
cGMP was not, indicating that both cyclic nucleotides might have
different sites of action, as is summarized in Figure 9.
The agents which increase cellular cAMP have been reported to
inhibit contraction of mesangial cells induced by various vasocon-
strictive peptides [9, 10]. These agents were also shown to inhibit
the proliferation of mesangial cells [11, 12]. However, the mech-
anism of the inhibitory effect of cAMP on mesangial cell prolif-
eration has not yet been clarified. Various vasoconstrictors, such
as ET-1, were found to bind to G protein-coupled receptors on
the surface of mesangial cells and to activate phospholipase C
resulting in the formation of inositol trisphosphate and diacylglyc-
erol [1]. An increase in cAMP was shown neither to inhibit
PDBu ET-1
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inositol trisphophate formation nor to interfere the increase in
Ca2 induced by vasoconstrictors in cultured mesangial cells [12,
40]. The present results indicate that cAMP inhibits the activation
of MAPK at a step possibly distal to PKC (Fig. 9). PKC was found
to activate Raf-1 [41, 42] by direct phosphorylation. Alternatively,
PKC was recently found to activate the novel tyrosine kinase
PYK2, which might interact with Grb2/Sos and activate Ras [431.
Thus, cAMP might inhibit ET-1- or PDBu-induced activation of
MAPK cascade at a step between Ras and Raf-i [27—311, as
suggested in the case of cAMP-induced inhibition of growth
factor-stimulated activation of MAPK cascade. However, the
response of MAPK cascade to cAMP seems to be dependent on
the types of cells. The activation of MAPK by cAMP was found in
certain types of cells such as COS-7 cells and PCI2 cells [32, 33],
and cAMP did not have any effect on MAPK in T lymphocytes
[34]. Therefore, mesangial cells are considered to be the cells in
which cAMP regulates the MAPK cascade negatively.
The agents that increase cellular cGMP have been also re-
ported to counteract the action of various vasoconstrictive pep-
tides. ANP, one of the cGMP-generating agents, was found to
inhibit the contraction of mesangial cells induced by angiotensin
II [7]. ANP was also found to inhibit the proliferation of mesan-
gial cells [13—15]. We have previously shown that ANP inhibits
ET-1-induced activation of MAPK [261. In the present study, a
cell-permeable analogue of cGMP, 8-Br-cGMP, was also able to
inhibit ET-1 -induced activation of MAPK cascade. However, the
site of inhibitory action of cGMP seems to be different from that
of cAMP because 8-Br-cGMP was not able to inhibit PDBu-
induced activation of MAPKK and MAPK. Thus, cGMP inhibits
ET-l -induced activation of MAPK cascade possibly at a step prior
to PKC (Fig. 9). Although we did not examine the effect of cGMP
on the binding of ET-1 to its receptors, the changes in ET-1
binding may not be the case because of the following reasons: (1)
ANP was shown not to compete with FT-i binding [441; (2) the
incubation period with cGMP in the present study was considered
to be too short to cause FT receptor down-regulation because the
ET receptor down-regulation was observed after 18 hours of
exposure to ET-1, and the brief exposure of the cells to phorbol
myristate acetate failed to induce significant changes in ET-1
binding [45]; and (3) 8-Br-cGMP did not alter the number or
affinity of thromboxane receptors, such as similar G protein-
coupled receptors like ET receptors [461. It is generally accepted
that cGMP reduces intracellular Ca2 by enhancing Ca2 effiux
from the cells [47, 48]. In addition, cGMP has been reported to
inhibit agonist-induced activation of PKC in vascular smooth
muscle cells and glomerular mesangial cells [46, 49]. This effect of
cGMP might be responsible for the inhibition of ET-1-induced
activation of MAPK cascade shown in the present study.
Interestingly, in the present study PDBu-induced activation of
MAPK cascade was not inhibited by 8-Br-cGMP, while ANP was
able to inhibit PDBu-induced activation of MAPK cascade. ANP
has been reported to inhibit the activities of adenylate cyclase and
to increase phosphatidylinositol turnover via a cGMP-indepen-
dent mechanism [50]. However, these effects of ANP are unlikely
to be responsible for the inhibition of PDBu-induced activation of
MAPK by ANP. ANP was also found to inhibit phorbol ester-
induced activation of PKC [46, 49, 511. Furthermore, Sauro and
Fitzpatrick have reported that phenylephrine-induced activation
of PKC was inhibited by both ANP and 8-Br-cGMP, while
PDBu-induced activation of PKC was inhibited only by ANP in
aortic smooth muscle [51]. Therefore, it can be speculated that
ANP could inhibit PDBu-induced activation of MAPK by inhibiting
PKC via cGMP-independent mechanisms, although further study
need to be performed to prove this hypothesis. Because the MAPK
cascade is one of the major signal transduction systems for cell
proliferation [16—18], these results may provide further evidence to
the finding that ANP inhibits the proliferation of mesangial cells by
both cGMP-dependent and cGMP-independent mechanisms [14].
Various functions of glomerular mesangial cells are considered
to be regulated by the interaction between vasoconstrictive sub-
stances, such as ET-1, and vasorelaxing substances which generate
cAMP or cGMP. MAPK cascade has been shown to be respon-
sible for not only cell proliferation and protein synthesis but also
the contractile responses [16—24]. Therefore, the cross talk be-
tween FT-i and cAMP or cGMP at the level of the MAPK
cascade shown in the present study is considered to be important
in the regulation of the functions of glomerular mesangial cells in
physiological and pathological conditions. Furthermore, the re-
sults also indicate that the underlying mechanisms of the effects of
cyclic nucleotides might be different.
Bt2-cAM P
Beraprost sodium
Adrenomedullin
8-Br-cGMP
ANP
Fig. 9. The mechanism of the inhibitoty effects of
cAMP- or cGMP-generating agents on ET-1- or
PDBu-induced activation of MAPK cascade in
cultured glomerular mesangial cells. R denotes
receptor. The mechanism of the inhibition of
PDBu-induced activation of MAPK cascade by
ANP is still unclear (see text).
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